ImmunoGen
Acquired by AbbVie
Is this your company?
ImmunoGen is now part of AbbVie. For up-to-date information, please see the AbbVie profile..
Find the right fit for you - faster
Get tailored insights about working at ImmunoGen in one quick step.
ImmunoGen Snapshot
Targeting a better life for people with cancer is why we get up in the morning.
It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. That’s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond.
Because for us, targeting a better now is the only thing that matters.
It’s not enough to disrupt the progress of someone’s cancer; we want to keep cancer from disrupting someone’s life. That’s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond.
Because for us, targeting a better now is the only thing that matters.
Incorporated in 1981, ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
